Sinopharm Tech Holdings Limited (8156) AI Stock Analysis

• Market Cap: HK$183.77M
• Dividend Yield: N/A
• Average Volume (3M): 51.70K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.27
• Revenue Growth: 48.39%
• EPS Growth: 88.30%
• Country: HK
• Employees: 30
• Sector: Technology
• Sector Strength: 88
• Industry: Software - Application
• EPS (TTM): <0.01
• Shares Outstanding: 633,693,050
• 10 Day Avg. Volume: 90,780
• 30 Day Avg. Volume: 51,702
• PEG Ratio: 1.01
• Price to Book (P/B): -2.33
• Price to Sales (P/S): 1.40
• P/FCF Ratio: -11.93
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: HK$0.50 ▲(127.27% Upside)

The overall stock score is primarily impacted by financial performance challenges, including negative profitability and high leverage. Technical analysis shows positive momentum, but overbought signals suggest caution. Valuation is weak due to a negative P/E ratio and lack of dividend yield.

Sinopharm Tech Holdings Limited Business Overview & Revenue Model

Company Description

Sinopharm Tech Holdings Limited (8156) is a diversified technology company based in Hong Kong, focusing primarily on healthcare, biotechnology, and the development of medical devices. The company operates across various sectors including pharmaceuticals, diagnostics, and health management systems, leveraging innovative technologies to enhance healthcare delivery. Sinopharm Tech is involved in the research, manufacturing, and distribution of medical products and solutions, aiming to meet the growing demands of the healthcare industry.

How the Company Makes Money

Sinopharm Tech Holdings Limited generates revenue through multiple streams, primarily from the sale of pharmaceutical products, medical devices, and healthcare solutions. The company partners with various healthcare institutions and organizations to provide integrated healthcare services and products, which contribute significantly to its income. Additionally, Sinopharm Tech engages in research and development activities, often collaborating with universities and research institutions to innovate new products. Revenue is also bolstered by government contracts and grants aimed at improving public health infrastructure, as well as strategic partnerships with other technology firms in the health sector.

Sinopharm Tech Holdings Limited Financial Statement Overview

Summary

Despite strong revenue growth of 224.12%, the company faces significant challenges with negative net profit and EBIT margins, negative stockholders' equity, and high leverage. Cash flow from operations is negative, although there is improvement in free cash flow growth.

Income Statement

The company has shown significant revenue growth of 224.12% in the latest year, indicating a strong recovery. However, profitability remains a concern with a negative net profit margin and EBIT margin, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, indicating financial instability. The high debt-to-equity ratio suggests significant leverage, posing a risk to financial health. The return on equity is not meaningful due to negative equity.

Cash Flow

Cash flow from operations is negative, which is concerning. However, there is a substantial improvement in free cash flow growth, suggesting potential for future cash generation. The ratios indicate cash flow challenges relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	61.25M	61.25M	41.28M	42.84M	40.98M	77.81M
Gross Profit	14.23M	13.52M	5.02M	5.47M	5.10M	20.88M
EBITDA	6.11M	6.11M	4.98M	-1.01M	-75.17M	-89.65M
Net Income	-867.00K	-867.00K	-19.70M	-10.63M	-88.00M	-106.34M
Balance Sheet
Total Assets	51.74M	51.74M	44.49M	33.48M	76.89M	135.90M
Cash, Cash Equivalents and Short-Term Investments	6.95M	6.95M	2.64M	1.78M	2.99M	7.48M
Total Debt	46.73M	46.73M	73.26M	53.00M	45.93M	108.03M
Total Liabilities	88.43M	88.43M	250.09M	213.24M	250.28M	276.46M
Stockholders Equity	-36.87M	-36.87M	-199.48M	-172.73M	-166.78M	-138.88M
Cash Flow
Free Cash Flow	-781.00K	-7.21M	-12.58M	4.73M	-36.88M	-16.32M
Operating Cash Flow	-5.69M	-7.21M	-9.25M	4.73M	-36.76M	-6.21M
Investing Cash Flow	-9.00K	-9.00K	-4.86M	2.00K	-85.00K	-5.05M
Financing Cash Flow	9.98M	11.50M	14.98M	-4.52M	32.24M	12.46M

Sinopharm Tech Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.22
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8156, the sentiment is Positive. The current price of 0.22 is below the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.26, and above the 200-day MA of 0.19, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 69.06 is Neutral, neither overbought nor oversold. The STOCH value of 36.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8156.

Sinopharm Tech Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
8131	53 Neutral	HK$69.52M	―	-523.99%	―	78.40%	72.37%
8100	52 Neutral	HK$97.78M	-20.95	-2.72%	1.00%	-13.40%	76.97%
8290	51 Neutral	HK$50.00M	-41.67	-2.07%	―	-6.88%	-100.00%
8156	45 Neutral	HK$183.77M	―	―	―	48.39%	88.30%
8036	45 Neutral	HK$35.77M	―	-0.42%	―	-14.25%	77.78%
8071	39 Underperform	HK$89.03M	―	-97.49%	―	-49.86%	15.00%